Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib with Durvalumab and Chemotherapy in ES-SCLC
NCT05668767Phase 2Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in small cell lung cancer (SCLC), sponsored by Beijing Chest Hospital. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05668767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668767.